000000427185 Robert K. Andrews	s, PhD	Associate Editor	Last Confir	med Date: 01/17/2024
Company:	Relationship:	Additional Info	ormation	End Date
Blood journal	Honoraria	Associate Editor	r of Blood	
National Health and Medical Research Council of Australia	Research Funding	Ideas grant		12/31/2024
Research Advisory Committee of the Australian Red Cross Blood Service	Membership on a Board or Advisory Committee	Member of the I Advisory Comm		
The Australian National University	Employment	Honorary Assoc Professor (Level		12/31/2024

000001007183	Philippe Armand, MD,PhD	Associate Editor	Last Confirmed Date: 01/17/2024
Company:	Relationship:	Additional Inform	ation End Date
	Consultancy	ATB Therapeutics	
	Consultancy	Foresight	
Adaptive	Research Funding		
ADC Therapeutics	Consultancy		
AstraZeneca	Consultancy		01/01/2023
AstraZeneca	Research Funding		
ATB Therapeutics	Consultancy	consultancy	
BMS	Consultancy		
BMS	Research Funding		
Enterome	Consultancy		
Epizyme	Consultancy		
Foresight	Consultancy	consultancy	
Genentech/Roche	Consultancy		01/01/2042
Genentech/Roche	Research Funding		
Genmab	Consultancy		
IGM	Research Funding		
Kite/Gilead	Research Funding		
Merck	Consultancy		01/01/2042
Merck	Research Funding		01/01/2042
Novartis	Research Funding		
Regeneron	Consultancy		

Tessa Consultancy
Xencor Consultancy

000002262303 Emily Arturo, PhD Staff Liaison to Committee Last Confirmed Date: 03/11/2024

Company: Relationship: Additional Information End Date

Nothing to disclose.

000000429043	Nizar Jacques Bahlis, MD	Associate Editor	Last Confi	rmed Date: 01/18/2024
Company:	Relationship:	Additional In	formation	End Date
Abbvie	Consultancy			
Abbvie	Honoraria			
Amgen	Consultancy			
Amgen	Honoraria			
Celgene / BMS	Consultancy			01/01/2040
Celgene / BMS	Honoraria			01/01/2040
Celgene / BMS	Research Funding			01/01/2040
Genentech	Consultancy			
Genentech	Honoraria			
GSK	Consultancy			
GSK	Honoraria			
Janssen	Consultancy			
Janssen	Honoraria			
Janssen	Research Funding			
Karyopharm	Consultancy			
Karyopharm	Honoraria			
Pfizer	Consultancy			
Pfizer	Research Funding			06/30/2022
Sanofi	Consultancy			
Sanofi	Honoraria			
Takeda	Honoraria			

000000123461	Nancy Berliner, MD	Editor	Last Confir	med Date: 01/17/2024
Company:	Relationship:	Additio	nal Information	End Date
Up To Date	Honoraria	Receive	for UpToDate. c honoraria for g chapters.	

000000123418	Mario Cazzola, MD		Special Section Editor	Last Confir	med Date: 01/17/2024
Company:		Relationship:	Additional Infor	mation	End Date
		Nothing to disclose.			
Incyte Corporation	ı	Membership on a Board Advisory Committee	or		

000000122721 Thomas D	. Coates, MD As	ssociate Editor Last Confi	rmed Date: 03/16/2024
Company:	Relationship:	Additional Information	End Date
Agios Pharma	Consultancy	consult regarding issues realted to thalassemia and iron overload	
Agios Pharma	Honoraria	consult as noted above	01/01/2025
Agios Pharma	Membership on a Board or Advisory Committee	Thalassemia advisory board	01/01/2025
Bluebird Bio	Consultancy	consult regarding thalassemia and sickle cell disease	01/01/2023
Bristol Meyers Squib	Consultancy	Participation in advisory committees, consulting	01/01/2025
Bristol Meyers Squib	Honoraria	for consulting / advisory comittee	01/01/2025
Bristol Meyers Squib	Membership on a Board or Advisory Committee	on sickle cell, thalassemia, iron advisory panels	01/01/2025
Celgene	Consultancy	have done advisory board in past	01/01/2023
Celgene	Honoraria	for advisory board	01/01/2023
Celgene	Research Funding	PI on two phase III clinical trials for Celgene related to thalassemia.	01/01/2023
Chiesi Farma	Consultancy	consult regarding iron overload and treament, thalassemia, sickle cell.	01/01/2025
Chiesi Farma	Honoraria	for consulting, advisory and consulting	01/01/2025
Forma pharma	Consultancy	Consult regarding sickle cell disease, thalassemia, iron	01/01/2024
Forma pharma	Membership on a Board or Advisory Committee		
UpToDate	Patents & Royalties	Receive royalties for chapters written for Up To Date	01/01/2025
Vifor Pharma	Consultancy	Consult regarding new hepcidin regulator	01/01/2023

000000425415 Jorge Di Paola, M	D Asso	ciate Editor Last Confirm	ned Date: 02/09/2024
Company:	Relationship:	Additional Information	End Date
	Membership on a Board or Advisory Committee	I am President of the American Society of Pediatric Hematology Oncology (ASPHO)	04/30/2022
Alnylam Pharmaceuticals	Consultancy	One time consultancy for drug development	02/01/2024
ASPHO	Membership on a Board or Advisory Committee	I am the President of the American Society of Pediatric Hematology Oncology (ASPHO)	04/30/2022
CSL Behring	Consultancy		
ISTH	Membership on a Board or Advisory Committee	I am a Member of the International Society of Thrombosis and Haemostasis (ISTH) Council	12/31/2024
NHLBI	Membership on a Board or Advisory Committee	Member of the PPG Parent Committee	01/01/2024
Pfizer	Membership on a Board or Advisory Committee	Member of a Data Safety and Monitoring Board (DSMB) for a new drug on phase 1	

000000427430	Herve Dombret, MD	Associate Editor	Last Confirm	ned Date: 12/15/2023
Company:	Relationship:	Additional Info	ormation	End Date
Amgen	Research Funding	Off-Label Drug Financial Suppo		01/01/2043
Astellas	Research Funding	Off-Label Drug Financial Suppo		01/01/2043
Celgene	Research Funding	Financial Suppo	ort	01/01/2043
Daiichy Sankyo	Consultancy	Consultant for E approval	EU product	01/01/2043
Daiichy Sankyo	Honoraria	Advisory Board		01/01/2043
Incyte	Research Funding	Off-Label Drug	Use	01/01/2043
Jazz Pharmaceutica	l Honoraria			06/30/2022
Jazz Pharmaceutica	Membership on a Boa Advisory Committee	rd or		06/30/2022
Jazz Pharmaceutica	l Research Funding	Off-Label Drug Financial Suppo		01/01/2043
Pfizer	Research Funding	Off-Label Drug Financial Suppo		01/01/2043
Servier	Research Funding	Financial Suppo	ort	01/01/2043

000000424814 Ja	son Gotlib, MD,MS	Associate Editor	Last Confirme	d Date: 01/29/2024
Company:	Relationship:	Additional Infor	rmation	End Date
	Research Funding			01/01/2028
Abbvie	Consultancy	Clinical trial PI		01/01/2023
Abbvie	Honoraria			01/01/2023
Abbvie	Research Funding			01/01/2026
Allakos	Consultancy			
Allakos	Honoraria	Received honora serving on an adv board in 2018-20	visory	01/01/2026
Allakos	Membership on a Board Advisory Committee	d or Served on an adv committee in 208 Allakos		01/01/2023
Blueprint Medicines	Honoraria	Honoraria and/or expense reimburs advisory board d and/or Steering C work	sement for uties	01/01/2028
Blueprint Medicines	Membership on a Board Advisory Committee	for Serve on an advisor for conduct of cli and Chair study so committee (for in advanced system mastocytosis)	inical trial steering ndolent and	01/01/2028
Blueprint Medicines	Research Funding	Receive funding of clinical trials	for conduct	01/01/2028
BMS	Research Funding	Clinical trial fund	ding	01/01/2025
Celgene	Honoraria			01/01/2023
Celgene	Research Funding	Funding for cond luspatercept trial.		01/01/2023
Cogent Biosciences	Consultancy			01/01/2028
Cogent Biosciences	Honoraria			01/01/2028
Cogent Biosciences	Membership on a Board Advisory Committee	d or		01/01/2028
Cogent Biosciences	Research Funding			01/01/2028
Deciphera	Consultancy	Serve on an advis for conduct of cli and Chair study s committee	inical trial	12/01/2022
Deciphera	Research Funding	Received funding conduct of clinical		12/01/2022
Gilead	Research Funding	Receive funding of clinical trials	for conduct	12/01/2022

Imago Biosciences	Consultancy		07/01/2023
Imago Biosciences	Honoraria		01/01/2023
Incyte	Honoraria	Honoraria and/or travel expense reimbursement for advisory board duties and/or Steering Committee work	01/01/2028
Incyte	Membership on a Board or Advisory Committee	Serve on an advisory board for conduct of clinical trials	01/01/2028
Incyte	Research Funding	Receive funding for conduct of clinical trials	01/01/2028
Kartos	Consultancy		01/01/2023
Kartos	Honoraria		01/01/2023
Kartos	Research Funding		01/01/2023
Merck	Research Funding	Clinical trial funding	01/01/2028
Novartis	Honoraria	Honoraria and/or travel expense reimbursement for advisory board duties and/or Steering Committee work	01/01/2023
Novartis	Membership on a Board or Advisory Committee	Serve on an advisory board for conduct of clinical trial and Chair study steering committee	01/01/2023
Novartis	Research Funding	Receive funding for conduct of clinical trials	01/01/2023
PharmaEssentia	Consultancy		01/01/2023
PharmaEssentia	Honoraria		01/01/2023
Promedior	Research Funding	Receive funding for conduct of clinical trial	12/01/2022
Protagonist Therapeutics	Research Funding	Clinical trial funding	01/01/2028
Telios	Research Funding	Clinical trial funding in ISM	01/01/2028

000001111295	Berthold Gottgens, PhD	Associate Editor	Last Confirmed Date: 01/18/2024

Company: Relationship: Additional Information End Date

Nothing to disclose.

000000122055	James D. Griffin, MD	Special Section Editor	Last Confirmed Dat	e: 01/29/2024
Company:	Relationship:	Additional Infor	mation	End Date
Analysis Group	Consultancy			
Astellas	Consultancy			01/01/2023
Astellas	Membership on a Bo Advisory Committee			
Novartis	Patents & Royalties			
Novartis	Research Funding			01/01/2040
Phios	Consultancy			
Phios	Equity Ownership			
Sun Pharma	Consultancy			01/01/2023

000000124273	Michael J. Hallek, MD	Associate Editor	Last Confir	med Date: 09/24/2021
Company:	Relationship:	Additional In	formation	End Date
AstraZeneca	Consultancy			
AstraZeneca	Membership on a Bo Advisory Committee			
AstraZeneca	Research Funding			
AstraZeneca	Speakers Bureau			
Gilead	Honoraria	occasional ad	boards	
Gilead	Research Funding	participation is	n a clinical tria	
Janssen	Honoraria			
Janssen	Membership on a Bo Advisory Committee			
Janssen	Research Funding			
Janssen	Speakers Bureau			
Mundipharma	Speakers Bureau			
Roche	Consultancy			
Roche	Honoraria			
Roche	Research Funding			

000000124176 Helen F	Elisabeth Heslop	Associate Editor	Last Confirm	Last Confirmed Date: 01/17/2024	
Company:	Relationship:	Additional Inf	formation	End Date	
Allovir	Equity Ownership	Co-founder and	d have shares	01/01/2035	
Allovir	Membership on a Board of Advisory Committee	or SAB member Viracyte chang Allovir	ged name to	01/01/2035	
Ankarys	Consultancy	SAB			
Fresh Wind Biotherapeutics	Consultancy	SAB			
Fresh Wind Biotherapeutics	Equity Ownership (Privat company)	e Potential for st	ock options		
GSK	Membership on a Board of Advisory Committee	or		01/01/2023	
Kuur Therapeutics	Research Funding	Clinical trial su contract to inst		05/01/2023	
Marker Therapeutics	Equity Ownership	co-founder and	l have shares	01/01/2039	
Marker Therapeutics	Membership on a Board of Advisory Committee	SAB member		01/01/2039	
Tessa Therapeutics	Consultancy	Advisory board	d	06/30/2023	
Tikva Allocell	Membership on a Board of Advisory Committee	or EAB			

000000423034	Diane Krause		Associate Editor	Last Confir	med Date: 03/12/2023
Company:		Relationship:	Additional Inf	formation	End Date
		Nothing to disclose.			
		Nothing to disclose.			

000000125037	Selina Luger, MD,FRCPC	Associate Editor	Last Confirmed Date: 02/1	3/2024
Company:	Relationship:	Additional I	nformation End D	ate
	Membership on a Boar Advisory Committee	rd or	01/01/2	2044
AbbVie	Membership on a Boar Advisory Committee	rd or	12/01/2	2022
Agios	Membership on a Boar Advisory Committee	rd or	01/01/2	2023
Amgen	Honoraria			
Amgen	Membership on a Boar Advisory Committee	rd or	01/01/2	2044
Astellas	Honoraria		01/01/2	2023
BMS	Honoraria		01/01/2	2023
Celgene	Research Funding		12/31/2	2022
Daiichi Sankyo	Membership on a Boar Advisory Committee	rd or		
kura	Research Funding		12/31/2	2022
MArker Therapeut	Membership on a Boar Advisory Committee	rd or	01/01/2	2024
Novartis	Consultancy		01/01/2	2024

000001003452	Laura Michaelis, MD	Special Section Editor	Last Confirmed Date: 11/04/2022
Company:	Relationship:	Additional Informa	ntion End Date
Celgene	Consultancy	Advisory	
Abbvie	Consultancy	1-time consultancy f	fee
Incyte	Consultancy	Legal witness	
JAZZ Pharmaceution	cals Membership on a Bo Advisory Committee		3
Novartis	Consultancy	1 time advisory boar participation	rd 12/31/2022

000000126102 Thomas L. Ortel, MD,PhD		Associate Editor	Last Confirm	ned Date: 02/14/2024
Company:	Relationship:	Additional Info	ormation	End Date
Instrumentation Laboratory	Consultancy	Provide recommended concerning hem testing.	11011000110	01/01/2024
Instrumentation Laboratory	Research Funding	Research suppo	ort	01/01/2025
Siemens	Research Funding	Coagulation-base and test develop	•	01/01/2025
Stago	Research Funding	Coagulation tes development	st	01/01/2025
Up To Date	Honoraria	Sections on antiphospholipi diagnosis and tr anticoagulation setting of endoc	reatment; in the	01/01/2025

000000428601 Andrew W. Roberts, MBBS,PhD		Deputy Editor Last Cont		nfirmed Date: 01/21/2024		
Company:		Relationship:	Additi	ional Information	End Date	
		Membership on a Board Advisory Committee	Cance	ian Comprehensive r Centre, Director on oard of Management		
Abbott		Research Funding				
AbbVie		Patents & Royalties	and El receive royalty Genen the deveneto Institu policy receive these received assign	nployer, the Walter iza Hall Institute es milestone and y payments from tech and AbbVie for velopment of oclax. Under the te's commercialization , I am eligible to e a small fraction of royalties (from Oct I also hold a patent I to venetoclax, wholly ed to AbbVie and for I receive no financial t.	01/01/2034	
AbbVie		Research Funding		ng for an investigator ed clinical trial. Paid to tion.	01/01/2034	
Abbvie (formerly Abb	pott)	Patents & Royalties	and El receive royalty Genen the de ABT-Institu policy receive fractio (from patent wholly and fo	nployer, the Walter iza Hall Institute es milestone and y payments from atech and AbbVie for velopment of 199. Under the te's commercialization, I am eligible to e and do receive a en of these royalties Oct 2018). I also hold related to venetoclax, y assigned to AbbVie r which I receive no ial benefit.	01/01/2034	
Australasian Leukaem Group	nia and Lymphoma	Membership on a Board Advisory Committee		r profit National al Trials Consortium	11/14/2023	

Cancer Council of Victoria Membership on a Board or Member of Medical and 05/01/2025 **Advisory Committee** Scientific Advisory Committee Not for profit organisation -Genentech Patents & Royalties Employee of Walter and Eliz Hall Institute which receives milestone payments relating to ABT-199 Genentech Patents & Royalties My employer, the Walter 01/01/2034 and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of venetoclax. Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018). I also hold patent related to venetoclax, wholly assigned to AbbVie and for which I receive no financial benefit. Genentech Research Funding South Australian immunoGENomics Membership on a Board or Member, Scientific Advisory Advisory Committee Cancer Institute (SAiGENCI) Board Membership on a Board or Victorian Comprehensive Cancer Centre Member of board of **Advisory Committee** management of Victorian Comprehensive Cancer Centre from Sept 2021 Walter and Eliza Hall Institute of Medical Patents & Royalties My employer, the Walter 01/01/2034 Research and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of venetoclax (formerly ABT-199). Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018).

000000127348	Irene Roberts		Associate Editor	Last Confir	med Date: 01/18/2024
Company:		Relationship:	Additional Inf	formation	End Date
		Nothing to disclose.			
		Nothing to disclose.			

000001000431	Laurie H. Sehn, MD		Special Section Editor	Last Confirmed Da	nte: 01/29/2024
Company:		Relationship:	Additional Inforn	nation	End Date
		Consultancy			01/01/2023
		Consultancy			01/01/2044
		Consultancy			01/01/2037
		Consultancy			01/01/2038
		Honoraria			01/01/2037
		Honoraria			01/01/2044
		Honoraria			01/01/2037
		Honoraria			01/01/2038
		Honoraria	Honoraria		01/01/2038
		Membership on a Board o Advisory Committee Research Funding	r		01/01/2038 01/01/2038
Abbvie		Honoraria			01/01/2030
Amgen		Consultancy			
Amgen		Honoraria			
Astra Zeneca		Consultancy			
Astra Zeneca		Honoraria			
Bristol Myers Squ	iibb	Consultancy			
Bristol Myers Squ	iibb	Honoraria			
Celgene		Honoraria			
Gilead		Consultancy			
Gilead		Honoraria			
Incyte		Consultancy			
Incyte		Honoraria			
Janssen		Honoraria			
Kite		Consultancy			
Kite		Honoraria			
Merck		Consultancy			
Merck		Honoraria			
Roche/Genentech		Consultancy			
Roche/Genentech		Honoraria			
Roche/Genentech		Research Funding			
Seagen		Consultancy			01/01/2044

Seagen

Conflict of Interest Disclosures Blood

Takeda Consultancy
Takeda Honoraria

Teva Consultancy 01/01/2041

Teva Honoraria 01/01/2041

Teva Research Funding

TG Therapeutics Consultancy
TG Therapeutics Honoraria

000001089568 Freda K. Stevenson, DPhil Associate Editor Last Confirmed Date: 09/29/2022

Company: Relationship: Additional Information End Date

Nothing to disclose.

Honoraria

Nothing to disclose. Nothing to disclose.

000000123573 Georgia B. Vogelsang, MD Special Section Editor Last Confirmed Date: 01/17/2024

Company: Relationship: Additional Information End Date

Nothing to disclose.

01/01/2044

000000423799 Erica M. Wood, MI	O Ass	ociate Editor La	st Confirmed Date: 01/30/2024
Company:	Relationship:	Additional Information	End Date
	Research Funding	Provision of drug for a clinical trial (where the clinical trial is funded by Australian Government Medical Research Futur Fund)	s
Abbvie, Amgen, AstraZeneca, Beigene, Celgene, CSL Behring, Gilead, Janssen, Novartis, Roche, Sanofi, Takeda	Research Funding	Research funding to my university for disease registries	12/31/2025
Australian and New Zealand Society of Blood Transfusion	Membership on a Board or Advisory Committee	Member, Research Advi Committee	sory 12/31/2026
International Society of Blood Transfusion	Membership on a Board or Advisory Committee	Immediate past presiden	t 06/30/2024
Sobi	Research Funding	Provision of drug for cli trial	nical 01/01/2026
Therapeutic Goods Administration, Australian Government	Membership on a Board or Advisory Committee	Chair, Advisory Commi on Biologicals	ttee 12/31/2026
World Health Organization	Membership on a Board or Advisory Committee	Co-chair, Advisory Committee on Blood Regulation, Availability Safety Member, WHO Guidelin Development Group on Donor Human Milk Ban Member, WHO Guidelin Development Group on Anaemia	ne king

000001005668	Robert Zeiser, MD		Associate Editor	Last Confir	med Date: 01/17/2024
Company:		Relationship:	Additional Info	ormation	End Date
		Honoraria	Speaker fee		
		Nothing to disclose.			
Incyte		Consultancy			
Mallinckroth		Honoraria			
Neovii		Honoraria	Speaker fee		
Novartis		Consultancy			
Novartis		Research Funding			09/01/2023
Sanofi		Consultancy			